NCCAM Targets Probiotics, Vitamin E, Curcumin, Devil’s Claw as Priorities for Large-Scale Trials

October 31, 2011

“While there are many areas of research with scientific promise and potential, NCCAM is currently accepting applications with an emphasis on [these] high-priority topics for CAM clinical research," NCCAM stated.

In an October update, the National Institutes of Health’s National Center for Complementary and Alternative Medicine (NCCAM) highlighted what it deems as priority areas of consideration for large-scale clinical trials. NCCAM says that it is currently accepting applications for research related to probiotics, curcumin, devil’s claw, and vitamin E.

  • Specifically for probiotics, NCCAM is considering research looking at biomarkers, safety, and appropriate dosage related to: 1) gut-barrier function in infants and children, 2) preventing antibiotic-induced diarrhea and enhancing influenza vaccine activity, 3) metabolic syndrome, and 4) atopic dermatitis or bacterial vaginosis.

  • For curcumin (Curcuma longa), NCCAM is targeting: 1) the bioavailability and effects of curcumin on musculoskeletal pain, and 2) effects on inflammatory bowel disorders. For devil’s claw (Harpagophytum procumbens), NCCAM is interested in effects on musculoskeletal pain. It also identifies butterbur (Petasites hybridus) as being of interest for migraines.

  • Finally, for vitamin E, NCCAM describes interest in effects on non-alcoholic steatohepatitis or non-alcoholic fatty liver disease.

“While there are many areas of research with scientific promise and potential, NCCAM is currently accepting applications with an emphasis on [these] high-priority topics for CAM clinical research. Investigators interested in pursuing other areas of research should consult the other funding opportunities available,” NCCAM stated in its update.

Nutritional Outlook thanks Harry Rice, PhD, for the tip.

Related Content:

News